FindTrial
Sign In

Prognostic value of ground-glass opacity on computed tomography in patients with pathological stage IA3 lung adenocarcinoma based on the micropapillary status: A multicenter study

Prognostic value of ground-glass opacity on computed tomography in patients with pathological stage IA3 lung adenocarcinoma based on the micropapillary status: A multicenter study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300077356
Enrollment
Unknown
Registered
2023-11-06
Start date
2023-11-09
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung adenocarcinoma

Interventions

GGO group:none
non-GGO group:none

Sponsors

Fujian Medical University Union Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1)Patients diagnosed with non-small cell lung cancer in four institutions in China from July 2012 to 2020 (Fujian Medical University Union Hospital , Putian First Hospital, Ningde Municipal Hospital of Ningde Normal University, and the First Hospital of Nanping ) were included (2) patients undergoing radical surgery (3) those undergoing lobectomy

Exclusion criteria

Exclusion criteria: The following exclusion criteria were used: (1) patients with multiple primary LUADs; (2) those undergoing wedge or segmental resection; (3) those lacking clinicopathological information or follow-up data; (4) those succumbing to mortality within 1 month postoperatively; (5) those with non-tumor-related deaths

Design outcomes

Primary

MeasureTime frame
Recurrence;Death;—

Countries

China

Contacts

Public ContactShuchen Chen

Fujian Medical University Union Hospital

cscdoctor@163.com+86 139 5020 7801

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026